Technical Analysis for KRTX - Karuna Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Range Bar | Range Expansion | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Inside Day | Range Contraction | 1.52% | |
| Gapped Up | Strength | 1.52% | |
| Oversold Stochastic | Weakness | 1.52% | |
| Slingshot Bearish | Bearish Swing Setup | 1.77% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Reversed from Down | about 12 hours ago |
| Down 1 ATR | about 14 hours ago |
| 60 Minute Opening Range Breakdown | about 14 hours ago |
| Outside Day | about 14 hours ago |
| Fell Below Previous Day's Low | about 14 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/01/2023
Karuna Therapeutics, Inc. Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's lead product candidate is KarXT, an oral modulator that is in Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia, as well as in Phase Ib clinical trial for the treatment of central nervous system disorders, such as cognitive and negative symptoms, Alzheimer's, and pain. It also focuses on developing other muscarinic-targeted drug candidates. Karuna Pharmaceuticals, Inc. has a license agreement with Eli Lilly and Company; and patent license agreement with PureTech Health LLC. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts. Karuna Therapeutics, Inc. operates as a subsidiary of PureTech Health plc.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Alzheimer's Disease Schizophrenia Central Nervous System Disorders Nervous System Disorders Treatment Of Central Nervous System Disorders Psychosis Puretech Health
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 245.0 |
| 52 Week Low | 159.73 |
| Average Volume | 244,809 |
| 200-Day Moving Average | 198.04 |
| 50-Day Moving Average | 182.80 |
| 20-Day Moving Average | 178.09 |
| 10-Day Moving Average | 170.45 |
| Average True Range | 5.40 |
| RSI (14) | 38.65 |
| ADX | 31.32 |
| +DI | 19.55 |
| -DI | 30.63 |
| Chandelier Exit (Long, 3 ATRs) | 176.75 |
| Chandelier Exit (Short, 3 ATRs) | 178.81 |
| Upper Bollinger Bands | 194.99 |
| Lower Bollinger Band | 161.20 |
| Percent B (%b) | 0.27 |
| BandWidth | 18.97 |
| MACD Line | -4.83 |
| MACD Signal Line | -4.09 |
| MACD Histogram | -0.7455 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 188.13 | ||||
| Resistance 3 (R3) | 187.60 | 181.11 | 185.15 | ||
| Resistance 2 (R2) | 181.11 | 176.56 | 181.38 | 184.16 | |
| Resistance 1 (R1) | 175.68 | 173.74 | 172.44 | 176.21 | 183.16 |
| Pivot Point | 169.19 | 169.19 | 167.57 | 169.46 | 169.19 |
| Support 1 (S1) | 163.76 | 164.64 | 160.52 | 164.29 | 157.34 |
| Support 2 (S2) | 157.27 | 161.82 | 157.54 | 156.34 | |
| Support 3 (S3) | 151.84 | 157.27 | 155.35 | ||
| Support 4 (S4) | 152.37 |
